Business Context and Reporting Period
This Form 8-K was filed by Flora Growth Corp., despite the request metadata identifying Zerostack Corp. The report concerns an underwriting agreement entered into on April 4, 2024, with the offering expected to close on April 8, 2024. Flora Growth’s common shares trade on the Nasdaq Capital Market under the symbol FLGC.
Transaction and Key Financial Metrics
- Flora agreed to issue and sell up to 1,700,000 common shares at $1.90 per share.
- Estimated net proceeds were approximately $2.8 million after underwriting discounts, commissions, and estimated offering expenses.
- Underwriting discounts were 7.0% for underwriter-introduced investors and 3.0% for company-introduced investors.
- Flora agreed to reimburse Aegis Capital Corp. for certain expenses, including legal fees, up to $75,000.
- The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures beyond the estimated offering proceeds.
Material Changes, Outlook, and Risks
- The transaction will increase the number of outstanding common shares by up to 1,700,000 and may result in dilution to existing shareholders.
- Flora and its executive officers and directors agreed, subject to exceptions, not to sell or transfer common shares or related securities for 90 days after the offering without Aegis’s written consent.
- The underwriting agreement includes customary representations, closing conditions, indemnification obligations, covenants, and termination provisions.
- The offering was conducted under Flora’s effective Form S-3 shelf registration statement, Registration No. 333-274204.
- Aegis Capital Corp. acted as sole underwriter. The filing does not state how the proceeds will be used or provide updated business guidance.
Investor Verification Items
- Confirm that the issuer is Flora Growth Corp., not Zerostack Corp., as identified in the request metadata.
- Verify whether the offering closed on April 8, 2024 and the actual number of shares issued.
- Confirm the final net proceeds and related underwriting and offering expenses.
- Review the underwriting agreement, legal opinion, and final prospectus for transaction terms and risk disclosures.
- Assess the resulting share dilution and the company’s intended use of the approximately $2.8 million in proceeds.